Evaluation of Cardioprotective Effects of Genistein against Diabetes-induced Cardiac Dysfunction in Rats by Tian, Heng-Song et al.
Tian et al 
Trop J Pharm Res, November 2015; 14(11): 2015  
 
Tropical Journal of Pharmaceutical Research November 2015; 14 (11): 2015-2022 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v14i11.10 
Original Research Article 
 
 
Evaluation of Cardioprotective Effects of Genistein against 
Diabetes-induced Cardiac Dysfunction in Rats 
 
Heng-Song Tian, Guo-Qing Zhou and Zhi-Yong Zhu 
Department of Cardiology, Pingmei ShenMa Medical Group General Hospital, Henan 467099, China 
 
*For correspondence: Email: hengsong2709@gmail.com; Tel/Fax: 0086-375-2799330 
 
Received: 6 February 2015        Revised accepted: 1 October 2015 
 
Abstract 
Purpose: To investigate the possible cardioprotective effects and potential pharmacological mechanism 
of genistein. 
Methods: Six-week old ZDF and lean rats were randomized into 4 groups (8 rats/group), including 
group 1 (control lean rats); group 2 (lean rats treated with genistein, 2.5 mg/kg); group 3 (control ZDF 
rats); and group 4 (ZDF treated with genistein). Two groups (2 and 4) were treated with genistein for 12 
weeks, and cardiac functions and metabolic alterations were determined. Macrophage/monocyte 
chemo-attractant protein-1 (MCP-1), vascular cellular adhesion molecule-1 (VCAM-1) and intracellular 
adhesion molecule-1 (ICAM-1) secretion and their messenger RNA transcription level also were 
observed. 
Results: Genistein attenuated diabetes-induced cardiac dysfunction and pathological alterations, by 
improving glucose tolerance and insulin resistance; facilitating Akt activation and glucose utilization, and 
attenuating oxidative stress and interrelated MAP kinase and NF-κB signalling pathways. In addition, 
genistein treatment markedly reduced diabetic-induced MCP-1 (83.33 %), VCAM-1 (74.66 %) and 
ICAM-1 (71.42 %) secretion and mRNA transcription in ZDF rats.  
Conclusion: The results demonstrate the putative effects of genistein against cardiovascular 
dysfunction by improving glucose homeostasis, attenuating oxidative stress and reduced diabetic-
induced endothelial dysfunction in ZDF rats. Thus, genistein is a potential candidate for the prevention 
of cardiovascular diseases.  
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The American Heart Association considers 
diabetes to be one of the seven major 
controllable risk factors for cardiovascular 
disease. Diabetic induced cardiovascular disease 
was characterized in ZDF rats by increased 
oxidative stress, apoptosis, fibrosis, 
inflammation, activation of MAP kinases and NF-
κB signalling and diminished Akt 
phosphorylation, along with decreased glucose 
transport, increased cardiac lipid accumulation, 
and ultimately diastolic dysfunction [1,2]. The 
most prevalent cardiovascular complications of 
diabetes, characterized by both systolic and 
diastolic dysfunction, due to reduced contractility, 
prolonged relaxation and decreased compliance, 
are diabetic cardiomyopathy [3] and 
atherosclerosis [4]. Endothelial dysfunction (ED) 
is an early event in atherosclerosis and plays a 
pivotal role in the atherogenesis process [5]. 
 
The emerging experimental data suggest that 
cardiac insulin resistance and metabolic 
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perturbations largely contribute to the 
development of cardiac dysfunction. The 
diminished glucose utilization and increased fatty 
acid oxidation in diabetic heart leads to lipid 
accumulation in myocardium [6]. An inflammatory 
response has already been shown to have an 
important role in the pathogenesis of myocardial 
ischemia- reperfusion injury [7]. Endothelial 
impairment can be detected in the early stage of 
atherosclerosis and serves as one of the leading 
mechanisms for HHcy-induced vascular 
dysfunction [8,9].   
 
Genistein, a major isoflavone abundant in soy, 
has been shown its potent vascular protective 
function [10,11]. Genistein could decrease ox-
LDL-induced ICAM-1 in human vascular 
endothelial cells [12], attenuate hyperglycemia-
induced MCP-1 expression in human aortic 
endothelial cells [13], and reduce 
lipopolysaccharide (LPS)-induced ICAM-1 and 
ICAM-1 in human endothelial cells [14]. 
However, the mechanisms have not been 
clarified. In the present study, we have 
demonstrated the cardio protective effect of 
genistein and its possible mechanism involved in 




Experimental animals  
 
Male ZDF (Zucker diabetic fatty) rats and age 
matched Zucker lean rats were housed in a 
temperature-controlled room under a 12/12 h 
light/dark cycle, with access to water and diet ad 
libitum. The 6 weeks old ZDF and lean rats were 
randomized into 4 groups (8 rats/group) such as 
group 1 -control lean rats; group 2- lean rats 
treated with genistein (2.5 mg/kg); group 3 - 
control ZDF rats; group 4 - ZDF treated with 
genistein. Genistein was dissolved in olive oil 
(total concentration 1 %) and administered 1 g 
daily for 12 weeks. Body weight and fasting 
glucose levels were measured weekly. Before 
sacrificing, an oral glucose tolerance test (GTT) 
was performed. The animals were maintained in 
accordance with the Chinese legislation 
guidelines and the international guidelines on the 
protection, care and handling of laboratory 
animals and all the protocols were approved by 
the Ethical Committee of Third Affiliated Hospital 
of Harbin Medical University, China (approval ref. 
no. CLG/PSMG-GH/2014/007983). 
 
Blood chemistry and metabolic analysis 
 
Serum samples were collected from rats that 
were fasted overnight and insulin levels 
determined (Insulin ELISA Kit from Millipore). For 
the GTT, D-glucose (2 g/kg body weight, Sigma 
Aldrich) was orally administrated after overnight 
fasting. Blood glucose was measured before, 
and after 30, 60 and 120 min of glucose uptake, 
using a commercially available glucometer 
(Bayer, IN). The area under the glucose curve 
(AUC) from 0–30, 0–60 and 0–120 min was 
calculated using the trapezoidal method [15]. 
Insulin sensitivity of individual animals was 
evaluated using the previously validated 
homeostasis model assessment (HOMA) index 
[16]. Plasma total cholesterol was measured 
using the polychromatic (452, 540, 700 nm) 
endpoint technique. The triglycerides (TG) and 
high-density lipoprotein (HDL) were measured 





The total RNA was extracted with Trizol 
(Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol. cDNA was synthesized 
with Revertaid First Stand cDNA Synthesis Kit 
(Fermentas). Real-time RT-PCR using Taq Man 
fluorescence methods were performed for 
quantitative analysis of mRNA. The products 
were amplified using Light Cycler II PCR 
machine (Roche Diagnostics, Basel, Switzerland) 
in the reaction mixture (20 ml) containing 2 ml of 
Light Cycler-Fast Start DNA Master Taqman 
(Roche, Tucson, AZ) and 0.5 mmol/L each 
primer. The primers specific for oxidative stress 
genes such as; SOD1, SOD2, Bcl2, Bax and 
Caspase-9; and primer specific for inflammatory 
marker such as; MCP-1, VCAM-1, ICAM-1, HO-1 
and β-actin were designed from Integrated DNA 
Technologies and synthesized from invitrogen 
(Life Technologies). By using Light Cycler 
Relative Quantification Software, the amount of 
target gene expression was calculated as a ratio 
of a target transcript relative to β-actin (a 




Transthoracic echocardiography was performed 
in anesthetized rats using HP sonos 5500 
(Hewlett-Packard) with a 12-MHz imaging 
transducer. Left ventricle (LV) wall thickness, 
diameter, systolic and diastolic function were 
analyzed as described previously [17], by an 





All the data were analyzed using SPSS13.0 
software (SPSS Inc, Chicago, IL, USA) and each 
experiment was performed at least three times,  
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all values were represented as mean ± SD; n=8. 
Comparisons between groups were tested by 
One-Way ANOVA analysis; p < 0.05 was 




Genistein mediated changes in body weight 
 
At 6 weeks of age, the ZDF rats had a higher 
body weight (BW) than the lean rats (252 ± 3 g 
vs 204 ± 5 g). The lean control rats gained BW 
steadily from 6 to 12 weeks, whereas the ZDF 
rats gained BW between 9 to 21 weeks, and 
there was no further gain from 21 to 25 weeks. 
Their BW was comparable to the lean rats at 8 
weeks (333 ± 7 g in ZDF vs 350 ± 6 g in the lean 
group) and lower at 12 weeks (340 ± 8 g in ZDF 
vs 320 ± 6 g in the lean group, p < 0.05). The 
effect of genistein on body weight was observed 
following 2 weeks of treatment. Rats receiving 
genistein for 2 weeks, significantly inhibited body 
weight gain in the ZDF rats. However, the 
untreated ZDF rats significantly gained BW 
through the experimental period (Table I). 
 
Genistein improve glucose homeostasis and 
cardiac glucose metabolism 
 
Fasting blood glucose levels were significantly 
elevated throughout the entire experimental 
period, in the untreated-ZDF rats (Table I), along 
with increased glucose tolerance (GTT), AUC-
GTT and HOMA-IR index at the age of 12 weeks 
(Fig 1, 2A), suggesting insulin resistance in ZDF 
rats. Genistein lowered the fasting glucose level 
and improved insulin resistance, as evidenced by 
the decreased GTT, AUCGTT and HOMA-IR 
index. The beneficial effect of RAR and RXR 
ligands on glucose metabolism was observed as 
early as 1 to 2 weeks following treatment (Fig 
2B), Genistein significantly lowered the blood 
glucose level (after 2 weeks of treatment: 260 ± 
12 mg/dL in ZDF+Genistein vs 478 ± 12 mg/dL in 
ZDF, p < 0.05) and HOMA-IR index (Fig 2C) 
after 2 weeks of treatment. Hyperinsulinemia was 
observed at age 6 weeks in ZDF rats (6.08 ± 
0.75 ng/dL in ZDF vs 0.44 ± 0.03 ng/dL in lean, p 
< 0.05). At age 12 weeks, the serum insulin level 
in the ZDF rats was decreased to a level 
comparable with the lean rats (0.71 ± 0.07 ng/dL 
in ZDF vs 0.76 ± 0.09 ng/dL in lean, (Fig. 2). This 
observation was accompanied by a significantly 
increased HOMA-IR index and decreased 
HOMA-β% index, suggesting that impaired β cell 
function may contribute to the decreased insulin 
level and progression of the diabetic process. At 
the age of 12 weeks, serum insulin was 
maintained at a higher level in the genistein 
treated ZDF rats (p < 0.05, vs ZDF), along with a 
decreased HOMAIR index and increased HOMA-
β% index, (Fig. 2D), suggesting that genistein 
treatment has beneficial effects on improving 
insulin resistance and β cell function. 
 
Genistein inhibit oxidative stress, apoptosis 
and activation of MAP kinases in ZDF rat 
hearts 
 
The results showed a significantly increased 
intracellular ROS generation (Fig. 3) and 
decreased expression of SOD1 and SOD2 in 
Figure 3A were observed in the ZDF rat’s hearts. 
Increased apoptosis was also observed in the 
ZDF rat’s hearts,  
 
  Table 1: Basic parameters for the study 
 
 Lean Lean+genistein ZDF ZDF+ genistein 
Body weight (g)     
0 week 204±5 199±2 252±3* 251±5* 
4 weeks  258±6 280±4 317±7* 288±9* 
8 weeks 313±4 307±4 333±7* 302±17# 
12 weeks 320±6 293±4 340±8 292±23* 
Blood glucose (mg/dL)     
0 week 63±2 86±29 73±5 94±5 
4 weeks  77±3 74±7 324±18* 161±12* 
8 weeks 79±42 76±4 336±12* 188±17* 
12 weeks 75±4 71±4 438±25* 161±34* 
At the end of the study     
HR(bpm/min) 264±5 261±9 232±7 247±12 
HW (g) 0.90±0.04 0.81±0.04 1.15±0.03* 0.85±0.02# 
HW/BW (mg/g) 1.70±0.06 1.79±0.05 2.95±0.03* 2.42±0.08 
HW/TL (mg/mm) 17.3±1.04 15.8±0.31 23.4±0.86* 19.0±0.49# 
Treatment started at the age of 6 weeks, 0 week = before treatment; HR = heart rate; 
HW = heart weight; BW - body weight; TL = tibia length; *p < 0.05, vs lean; #p < 0.05, vs 
ZDF 
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Figure 1: Represent the glucose level monitored during GTT in lean and ZDF rats with the treatment of genistein. 
Glucose levels were measured at 0, 30, 60 and 120 min following glucose uptake. Values are expressed as 
mean ± SEM (n=8); *p < 0.05 vs ZDF group 
 
 
Figure 2:  Represent the measurement of AUC based on GTT results (A). The level of plasma insulin (B), 
HOMA-IR (C) and HOMA-β% (D) were determined at the end of the experiment. Values are expressed as the 
mean ±SEM (n=8). * p<0.05 vs ZDF group 
 
as evidenced by decreased expression of Bcl2, a 
decreased Bcl2/Bax ratio and increased 
expression of Bax, caspase 9 and TUNEL-
positive myocytes (23 %) (Fig. 3B, C). Genistein 
inhibited ROS generation and the activated MAP 
kinases and apoptotic signaling, as well as the 
percent of TUNEL-positive myocytes (10 and 2.3 
%, respectively, p < 0.05, vs ZDF). These data 
suggest that genistein inhibits apoptosis of 
cardiomyocyte, by reducing oxidative stress and 
associated MAP kinase pathways. 
 
Effects of genistein on mRNA levels of MCP-
1, VCAM-1, ICAM-1 and HO-1 
 
The mRNA levels of MCP-1, VCAM-1 and ICAM-
1 were analyzed using real-time RT-PCR. The 
mRNA levels in untreated ZDF rats showed a 
marked increases of MCP-1 (9.09 %), VCAM-1 
(20 %) and ICAM-1(21.42 %) secretion 
compared with lean (p < 0.05); however, 
treatment with genistein would significantly inhibit 
MCP-1 (83.33 %), VCAM-1 (74.66 %) and ICAM-
1 (71.42 %) secretion compared with ZDF rats 
(Fig 4A). 
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Figure 3: Represent the effect of genistein against 
oxidative stress in Lean and ZDF rats. The mRNA 
levels of SOD1 & SOD2 (A), the mRNA levels of Bcl2, 
Bax and Caspase 9 (B), and the graphical 
representation of percentage of ROS stainging & 
TUNNEL positive cells (C). Values are expressed as 
the mean ±SEM (n=3); *p < 0.05 vs ZDF group 
 
This result suggests the inhibitory effects of 
genistein on pro-inflammatory cytokine secretion. 
The mRNA level of HO-1 was significantly (p < 
0.05) increased by genistein administration in 
both the lean and ZDF rats (Fig. 4B). 
Interestingly, our report demonstrate that 
genistein control the inflammatory marker by 
enhancing the HO-1 expression. 
 
  
Figure 4: Represent the mRNA levels of inflammatory 
markers (A) and HO-1 (B) of cardiac tissue from the 
experimental groups. Values are expressed as mean ± 
SEM (n = 8). *p < 0.05, vs ZDF group 
 
Effect of genistein on left ventricular 
structural and functional changes 
 
There was no difference observed in heart rate 
between the groups (Table I). Increased heart 
weight (HW), HW/BW ratio and HW/TL (tibia 
length) ratio were observed in untreated-ZDF 
rats (p < 0.05, vs lean control). Due to changes 
in the body weight between groups, we used the 
HW/TL ratio, as an index, to compare the effect 
of genistein on cardiac hypertrophy. Genistein 
significantly inhibited the increased HW/TL in 
ZDF rats (29 ± 0.49 mg/mm in ZDF + Am vs 33.4 
± 0.86 mg/mm in ZDF, p < 0.05). A significantly 
increased thickness of the systolic posterior wall 
of the LV (LVPWs), along with decreased systolic 
inner diameter of the LV was observed in 
untreated ZDF rats at 12 weeks of age (Fig 5A), 
representing a concentric cardiac hypertrophy, 
which was not observed in genistein treated ZDF 
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rats. The increased HW/TL and LVPWs were in 
line with the increased expression of the 
hypertrophic markers ANP and BNP (Fig 5B). 
There was no significant decrease in LV ejection 
fraction (LVEF) and fractional shortening (FS) in 
ZDF rats, suggesting no significant systolic 
dysfunction in ZDF rats, at 12 weeks of age. 
However, a significantly decreased E/A ratio, and 
increased IVRT and DT were observed (data not 
shown) in ZDF rats, at 8 and 12 weeks of age (p 
< 0.05, vs lean rats), indicating that diastolic 




Figure 5: Represent the Echocardiographic studies performed for 6 and 12 weeks in lean and ZDF rats 
administered with genistein with a special focus to LVPWs (A) and LVIDs (B). Values are expressed as the mean 
± SEM (n = 8); *p < 0.05, vs ZDF group 
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The present study demonstrated that genistein 
ameliorated diabetes-induced cardiac 
dysfunction and other pathological alterations. 
Genistein, a major isoflavone abundant in soy, 
has been shown its potent cardiovascular 
protective function [10,11]. The beneficial effects 
of genistein may be associated with the 
mechanisms like improvement of the impaired 
cardiac insulin metabolic signalling by reducing 
systemic hyperglycemia and insulin resistance; 
enhancement of cardiac glucose 
uptake/utilization and reducing glucotoxity-
induced oxidative stress; inhibition of MAP 
kinases activation and amelioration of cardiac 
inflammatory responses.  
 
In the present study, hyperinsulinemia, 
hyperglycemia, hyperlipidemia and insulin 
resistance were observed in ZDF rats.  Diabetic 
induced cardiac dysfunction as evidenced by 
diastolic dysfunction with hypertrophy, fibrosis, 
inflammation and apoptosis developed in ZDF 
rats.  
 
Our results showed significantly increased 
HOMA-IR index and decreased HOMA-β% index 
in ZDF rats, suggesting that impaired β cell 
function may contribute to the decreased insulin 
level and development of the diabetes. This 
observation was consistent with previous studies, 
which showed a decreased serum insulin level in 
aged ZDF rats [18,19]. A number of factors could 
contribute to the pathological effects observed. 
The hyperglycemia and hyperlipidemia-induced 
intracellular generation of ROS can act as signal 
transduction molecules to activate various 
signalling pathways, which ultimately lead to an 
inflammation, a cell apoptosis and fibrosis 
[20,21]. We observed significantly increased 
oxidative stress, apoptosis, inflammatory 
responses and activation of MAP kinases in ZDF 
rats. However, genistein administration have 
prevented these effects may be due to the anti-
oxidation and anti-angiogenesis effects as well 
as estrogenic activities of genistein [22]. 
Increased ROS (reactive oxygen species) 
formation activates MAP kinase-signalling 
pathways and promotes cardiomyocyte 
apoptosis [23,24]. Our data further confirmed that 
diabetes-induced oxidative stress plays vital role 
in regulation of the development of diabetic 
complications. Insulin resistance reduces 
phosphorylation of Akt pathway, which is 
involved in regulation of genes that control 
glucose and lipid homeostasis and other cellular 
processes like cellular hypertrophy, protein 
translation, nitric oxide generation, and apoptosis 
[25,26]. The mechanisms involved in cardio 
protective function of genistein are obscure. 
Besides its non-specific tyrosine kinase inhibitory 
role, genistein could exert vascular protective 
action through many other signaling pathways, 
such as cAMP/protein kinase A and PI3 K/AKT 
pathways [27].  
 
Furthermore, we analyzed the cardiac 
inflammatory response, where the increased 
mRNA level of MCP-1, VCAM-1 and ICAM-1 
found in untreated ZDF rats. However, genistein 
significantly inhibited diabetic-induced MCP-1, 
VCAM-1 and ICAM-1 expression. This is 
consistent with the previous report that genistein 
increased heme oxygenase (HO) activity, where 
HO system is tightly involved in the inhibitory 
activities of genistein against inflammation [28]. 
This part of our study showed that the down 
regulation of the expression levels of MCP-1, 
VCAM-1 and ICAM-1 was achieved by genistein 




Altogether, the findings reveal the protective 
effect of genistein on cardiovascular dysfunction 
by maintaining glucose homeostasis and cardiac 
glucose metabolism, inhibiting oxidative stress, 
apoptosis and activation of MAP kinases and 
prevention of inflammatory response. Thus, 
administration of genistein against cardiovascular 
diseases may be a positive approach to the 




1. Daniels A, Linz D, van Bilsen M, Rutten H, Sadowski T, 
Ruf S,  Juretschke HP, Neumann-Haefelin C, Munts 
C, vander Vusse GJ, van Nieuwenhoven FA. . Long-
term severe diabetes only leads to mild cardiac 
diastolic dysfunction in Zucker diabetic fatty rats. Eur 
J Heart Fail 2012; 14: 193–201.  
2. Baynes J, Murray DB. Cardiac and renal functions are 
progressively impaired with aging in Zucker diabetic 
fatty type II diabetic rats. Oxid Med Cell Longev 2009; 
2: 328–334. 
3. Murarka S, Movahed MR. Diabetic cardiomyopathy. J 
Card Fail 2010; 16: 971–979. 
4. Werner N, Nickenig G. Influence of cardiovascular risk 
factors on endothelial progenitor cells: limitations for 
therapy? Arterioscler Thromb Vasc Biol 2006; 26: 
257–266. 
5. Bonetti PO, Lerman LO, Lerman A. Endothelial 
dysfunction: a marker of atherosclerotic risk. 
Arterioscler Thromb Vasc Biol 2003; 23: 168–175. 
6. Feuvray D, Darmellah A. Diabetes-related metabolic 
perturbations in cardiac myocyte. Diabetes Metab 
2008; 34: S3–S9. 
Tian et al 
Trop J Pharm Res, November 2015; 14(11): 2022  
 
7. Lucchesi, BR. Modulation of leukocyte-mediated 
myocardial reperfusion injury. Annu Rev Physiol 
1990; 52: 561- 566. 
8. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp 
HR, and Haynes WG. “Role of oxidant stress in 
endothelial dysfunction produced by experimental 
hyperhomocyst(e)inemia in humans,” Circulation 
1999; 100: 1161–1168. 
9. Eberhardt RT, Forgione MA. Cap A, Leopold JA, Rudd 
MA, Trolliet M,  Heydrick S, Stark R, Klings ES, 
Moldovan NI et al. “Endothelial dysfunction in a 
murine model of mild hyperhomocyst(e)inemia,” J 
Clin Investig 2000; 106: 483–491. 
10. Si H, and Liu D. “Phytochemical genistein in the 
regulation of vascular function: new insights,” Curr 
Med Chem 2007; 14: 2581–2589,  
11. Rimbach G, Boesch-Saadatmandi C, Frank J.  Fuchs D, 
Wenzel U, Daniel H, Hall WL, Weinberg PD. “Dietary 
isoflavones in the prevention of cardiovascular 
disease—a molecular perspective,” Food Chem 
Toxicol, 2008; 46: 1308–1319. 
12. Yi L, Jin X, Chen CY, Fu YJ, Zhang T, Chang H, Zhou Y, 
Zhu JD, Zhang QY, and Mi MT.* Chemical structures 
of 4-oxo-flavonoids in relation to inhibition of oxidized 
low-density lipoprotein (LDL)-induced vascular 
endothelial dysfunction. Int J Mol Sci 2011; 12: 5471-
5489. 
13. Babu PV, Si H, Fu Z, Zhen W,  Liu D. *Genistein prevents 
hyperglycemia-induced monocyte adhesion to human 
aortic endothelial cells through preservation of the 
cAMP signaling pathway and ameliorates vascular 
inflammation in obese diabetic mice. J Nutr 2012; 
142: 724-730. 
14. De Andrade CM, De Sa MF, Toloi MR. Effects of 
phytoestrogens derived from soy bean on expression 
of adhesion molecules on HUVEC. Climacteric 2012; 
15: 186-194. 
15. Purves RD. Optimum numerical integration methods for 
estimation of area under-the-curve (AUC) and area-
under-the-moment-curve (AUMC). J Pharmacokinet 
Biopharm 1992; 20: 211–226. 
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, 
Treacher DF, Turner RC. Homeostasis model 
assessment: insulin resistance and beta-cell function 
from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 1985; 28: 412–
419. 
17. Choudhary R, Palm-Leis A, Scott RC, Guleria RS, 
Rachut E, Baker KM. All-trans retinoic acid prevents 
development of cardiac remodeling in aortic banded 
rats by inhibiting the renin-angiotensin system. Am J 
Physiol Heart Circ Physiol 2008; 294: H633–H644. 
18. Fulop N, Mason MM, Dutta K, Wang P, Davidoff AJ, 
Marchase RB. Impact of Type 2 diabetes and aging 
on cardiomyocyte function and O-linked N-
acetylglucosamine levels in the heart. Am J Physiol 
Cell Physiol 2007; 292: C1370–C1378. 
19. Toblli J, Cao G, Rivas C, Munoz M, Giani J, Dominici F. 
Cardiovascular protective effects of nebivolol in 
Zucker diabetic fatty rats. J Hypertens 2010; 
28:1007–1019. 
20. Selvaraju V, Joshi M, Suresh S, Sanchez JA, Maulik N, 
Maulik G. Diabetes, oxidative stress, molecular 
mechanism, and cardiovascular disease--an 
overview. Toxicol Mech Methods 2012; 22: 330–335. 
21. Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal 
PK. Oxidative stress: a key contributor to diabetic 
cardiomyopathy. Can J Physiol Pharmacol 2010; 88: 
233–240. 
22. Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL, Liu HS, 
Cheng HL, Hsu PY, Chow NH. The novel targets for 
anti-angiogenesis of genistein on human cancer cells. 
Biochem Pharmacol 2005; 69: 307–18. 
23. Thandavarayan RA, Watanabe K, Ma M, Gurusamy N, 
Veeraveedu PT, Konishi T. Zhang S, Muslin AJ, 
Kodama M, Aizawa Y. Dominant-negative p38alpha 
mitogen-activated protein kinase prevents cardiac 
apoptosis and remodeling after streptozotocin-
induced diabetes mellitus. Am J Physiol Heart Circ 
Physiol 2009; 297: H911–H919. 
24. Tsai KH, Wang WJ, Lin CW, Pai P, Lai TY, Tsai CY, Kuo 
WW. NADPH oxidase-derived superoxide anion-
induced apoptosis is mediated via the JNK-
dependent activation of NF-kappaB in 
cardiomyocytes exposed to high glucose. J Cell 
Physiol 2012; 227: 1347–1357. 
25. Muniyappa R, Montagnani M, Koh KK, Quon MJ. 
Cardiovascular actions of insulin. Endocr Rev 2007; 
28: 463–491. 
26. Rask-Madsen C, Kahn CR. Tissue-specific insulin 
signaling, metabolic syndrome, and cardiovascular 
disease. Arterioscler Thromb Vasc Biol 2012; 32: 
2052–2059.  
27. Zheng FL, Zhao JH, Zhang HP, “The action of PI3K/AKT 
during genistein promoting the activity of eNOS,” 
Zhonghua Xin Xue Guan Bing Za Zhi, 2012; 40: 327–
331. 
28. Zhang HP, Zheng FL, Zhao JH, Guo DX, Chen XL. 
Genistein inhibits ox-LDL-induced VCAM-1, ICAM-1 
and MCP-1 expression of HUVECs through heme 
oxygenase-1. Arch Med Res 2013; 44:13-20. 
 
